Pandion Therapeutics - Modular Biologics for Autoimmune Regulation

Merck to Acquire Pandion Therapeutics
Acquisition Adds Pipeline of Candidates Targeting a Broad Range of Autoimmune Diseases More

Our TALON™ Platform is built to create modular protein therapeutics for systemic and local immune regulation

Our pipelineis built to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases

latest news

February 25, 2021: Merck to Acquire Pandion Therapeutics

February 22, 2021: Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting

February 22, 2021: Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting